Experts at SICP 2025 outline how molecular mechanisms and bedside assessments can guide personalised treatment for neuropathic pain in oncology.

Regarding “Your Health: What Influencers Get Wrong About Antidepressants” (Personal Journal, Nov. 12): Another side effect users should know is that clinical bone healing appears to be negatively ...

EXXUA is a novel oral selective serotonin 5HT1a receptor agonist indicated for the treatment of major depressive disorder (MDD) in adults. EXXUA is also being developed for other psychiatric disorders ...

EXXUA is now available through Aytu RxConnect pharmacies to ensure optimal access and availabilityEXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving mor ...

The GNPS Drug Library may be more broadly applicable for drug screening across diverse research disciplines, such as food and environmental monitoring.

China Medical System Holdings Limited (the 'Group” or 'CMS”) is pleased to announce that on 11 December 2025, the New Drug ...

Dr. Wen-Han Chang, corresponding author, added, “The work highlights why biomarkers cannot be interpreted in isolation. Tumor context—immune composition, metabolic state, and innate ...

Alleviate your low mood with the help of light therapy, meditation, caffeine swaps and more expert-recommended tips ...

Psilocybin, the psychoactive compound in so-called magic mushrooms, is emerging as one of the most intriguing tools in modern ...

Former staff allege bullying, misogyny and safeguarding lapses at the city-state outpost of North London Collegiate School ...

Detailed price information for Oncotelic Therapeutics Inc (OTLC) from The Globe and Mail including charting and trades.